Document is current
Any future updates will be listed below
-
Authors
Wu, Renee
Ohara, Ray A. https://orcid.org/0000-0001-7897-3169
Jo, Suin
Liu, Tian-Tian https://orcid.org/0000-0001-9377-9938
Ferris, Stephen T. https://orcid.org/0000-0003-3340-2607
Ou, Feiya
Kim, Sunkyung
Theisen, Derek J.
Anderson, David A. III
Wong, Brian W. https://orcid.org/0000-0001-8447-3064
Gershon, Timothy
Schreiber, Robert D.
Murphy, Theresa L.
Murphy, Kenneth M. https://orcid.org/0000-0002-3505-9630
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA248919-02, F30 CA247262, R01CA190700, R01CA248919)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1R21AI163421-01A1, 1R01AI162643-01A1, 5R01AI150297-04, 1R21AI164142-01A1, 5R01AI150297, R21AI164142)
- License Information
-
More Information
Article History
Received: 21 December 2021
Accepted: 7 September 2022
First Online: 21 October 2022
Competing interests
: R.D.S. is a co-founder, paid consultant and stockholder of Jounce Therapeutics and Asher Biotherapeutics and paid consultant and stockholder of A2 Biotherapeutics, Arch Oncology, Asher Biotherapeutics, Codiak Biosciences, NGM Biotherapeutics, Meryx and Sensei Biotherapeutics. K.M.M. is a paid member of the scientific advisory board of Harbour BioMed. The other authors declare no competing interests.
